{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:34:23Z","timestamp":1790022863351,"version":"4.0.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2006,12,5]],"date-time":"2006-12-05T00:00:00Z","timestamp":1165276800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,12,5]],"date-time":"2006-12-05T00:00:00Z","timestamp":1165276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1007\/s00262-006-0247-2","type":"journal-article","created":{"date-parts":[[2006,12,4]],"date-time":"2006-12-04T09:01:45Z","timestamp":1165222905000},"page":"997-1007","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice"],"prefix":"10.1007","volume":"56","author":[{"given":"Jorge G.","family":"Gomez-Gutierrez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kutlu G.","family":"Elpek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Montes de Oca-Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haval","family":"Shirwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Sam Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.","family":"McMasters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,12,5]]},"reference":[{"key":"247_CR1","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S1071-5576(02)00166-1","volume":"9","author":"MA Steller","year":"2000","unstructured":"Steller MA (2000) Cervical cancer vaccines: progress and prospects. J Soc Gynecol Investig 9:254\u2013264","journal-title":"J Soc Gynecol Investig"},{"key":"247_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","volume":"189","author":"JM Walboomers","year":"1999","unstructured":"Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12\u201319","journal-title":"J Pathol"},{"key":"247_CR3","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1128\/JVI.63.11.4898-4903.1989","volume":"63","author":"EM de Villiers","year":"1989","unstructured":"de Villiers EM (1989) Heterogeneity of the human papillomavirus group. J Virol 63:4898\u20134903","journal-title":"J Virol"},{"key":"247_CR4","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1093\/jnci\/87.11.796","volume":"87","author":"FX Bosch","year":"1995","unstructured":"Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst 87:796\u2013802","journal-title":"J Natl Cancer Inst"},{"key":"247_CR5","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1073\/pnas.86.2.563","volume":"86","author":"G Pecoraro","year":"1989","unstructured":"Pecoraro G, Morgan D, Defendi V (1989) Differential effects of human papillomavirus type 6, 16, and 18 DNAs on immortalization and transformation of human cervical epithelial cells. Proc Natl Acad Sci USA 86:563\u2013567","journal-title":"Proc Natl Acad Sci USA"},{"key":"247_CR6","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1128\/JVI.65.1.292-298.1991","volume":"65","author":"MS Barbosa","year":"1991","unstructured":"Barbosa MS, Vass WC, Lowy DR, Schiller JT (1991) In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential. J Virol 65:292\u2013298","journal-title":"J Virol"},{"key":"247_CR7","first-page":"197","volume":"12","author":"K Munger","year":"1992","unstructured":"Munger K, Scheffner M, Huibregtse JM, Howley PM (1992) Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv 12:197\u2013217","journal-title":"Cancer Surv"},{"key":"247_CR8","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1126\/science.2537532","volume":"243","author":"N Dyson","year":"1989","unstructured":"Dyson N, Howley PM, Munger K, Harlow E (1989) The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934\u2013937","journal-title":"Science"},{"issue":"Pt 6","key":"247_CR9","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1099\/0022-1317-80-6-1513","volume":"80","author":"M Thomas","year":"1999","unstructured":"Thomas M, Banks L (1999) Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. J Gen Virol 80(Pt 6):1513\u20131517","journal-title":"J Gen Virol"},{"key":"247_CR10","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1006\/viro.1997.8885","volume":"239","author":"DJ Armstrong","year":"1997","unstructured":"Armstrong DJ, Roman A (1997) The relative ability of human papillomavirus type 6 and human papillomavirus type 16 E7 proteins to transactivate E2F-responsive elements is promoter- and cell-dependent. Virology 239:238\u2013246","journal-title":"Virology"},{"key":"247_CR11","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1002\/(SICI)1097-0142(19991115)86:10<2021::AID-CNCR20>3.0.CO;2-1","volume":"86","author":"YB Dong","year":"1999","unstructured":"Dong YB, Yang HL, Elliott MJ, Liu TJ, Stilwell A, Atienza C Jr, McMasters KM (1999) Adenovirus-mediated E2F-1 gene transfer efficiently induces apoptosis in melanoma cells. Cancer 86:2021\u20132033","journal-title":"Cancer"},{"key":"247_CR12","first-page":"3590","volume":"7","author":"MJ Elliott","year":"2001","unstructured":"Elliott MJ, Dong YB, Yang H, McMasters KM (2001) E2F-1 up-regulates c-Myc and p14(ARF) and induces apoptosis in colon cancer cells. Clin Cancer Res 7:3590\u20133597","journal-title":"Clin Cancer Res"},{"key":"247_CR13","doi-asserted-by":"publisher","first-page":"8206","DOI":"10.1038\/sj.onc.1208012","volume":"23","author":"S Duensing","year":"2004","unstructured":"Duensing S, Duensing A, Lee DC, Edwards KM, Piboonniyom SO, Manuel E, Skaltsounis L, Meijer L, Munger K (2004) Cyclin-dependent kinase inhibitor indirubin-3\u2032-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies. Oncogene 23:8206\u20138215","journal-title":"Oncogene"},{"key":"247_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1146\/annurev.med.55.091902.103520","volume":"55","author":"KU Jansen","year":"2004","unstructured":"Jansen KU, Shaw AR (2004) Human papillomavirus vaccines and prevention of cervical cancer. Annu Rev Med 55:319\u2013331","journal-title":"Annu Rev Med"},{"key":"247_CR15","first-page":"124","volume":"49","author":"H Furumoto","year":"2002","unstructured":"Furumoto H, Irahara M (2002) Human papilloma virus (HPV) and cervical cancer. J Med Invest 49:124\u2013133","journal-title":"J Med Invest"},{"key":"247_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1248\/bpb.27.303","volume":"27","author":"X Zhou","year":"2004","unstructured":"Zhou X, Qian X, Zhao Q, Lu Y, Xiong M (2004) Efficient expression of modified human papillomavirus 16 e6\/e7 fusion protein and the antitumor efficacy in a mouse model. Biol Pharm Bull 27:303\u2013307","journal-title":"Biol Pharm Bull"},{"key":"247_CR17","doi-asserted-by":"publisher","first-page":"16232","DOI":"10.1073\/pnas.192581299","volume":"99","author":"J Li","year":"2002","unstructured":"Li J, Sun Y, Garen A (2002) Immunization and immunotherapy for cancers involving infection by a human papillomavirus in a mouse model. Proc Natl Acad Sci USA 99:16232\u201316236","journal-title":"Proc Natl Acad Sci USA"},{"key":"247_CR18","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1172\/JCI200112346","volume":"108","author":"WF Cheng","year":"2001","unstructured":"Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M, Wu TC (2001) Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 108:669\u2013678","journal-title":"J Clin Invest"},{"issue":"25","key":"247_CR19","doi-asserted-by":"publisher","first-page":"15101","DOI":"10.1073\/pnas.2135379100","volume":"100","author":"L Zhang","year":"2003","unstructured":"Zhang L, Tang Y, Akbulut H, Zelterman D, Linton P-J, Deisseroth AB (2003) An adenoviral vector cancer vaccine that delivers a tumor-associated antigen\/CD40-ligand fusion protein to dendritic cells. Proc Natl Acad Sci USA 100(25):15101\u201315106","journal-title":"Proc Natl Acad Sci USA"},{"key":"247_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/BF00925962","volume":"135","author":"PD Nash","year":"1994","unstructured":"Nash PD, Opas M, Michalak M (1994) Calreticulin: not just another calcium-binding protein. Mol Cell Biochem 135:71\u201378","journal-title":"Mol Cell Biochem"},{"key":"247_CR21","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1074\/jbc.270.28.17011","volume":"270","author":"EM Conway","year":"1995","unstructured":"Conway EM, Liu L, Nowakowski B, Steiner-Mosonyi M, Ribeiro SP, Michalak M (1995) Heat shock-sensitive expression of calreticulin. In vitro and in vivo up-regulation. J Biol Chem 270:17011\u201317016","journal-title":"J Biol Chem"},{"key":"247_CR22","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1084\/jem.189.5.797","volume":"189","author":"S Basu","year":"1999","unstructured":"Basu S, Srivastava PK (1999) Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity. J Exp Med 189:797\u2013802","journal-title":"J Exp Med"},{"key":"247_CR23","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1002\/eji.1830270944","volume":"27","author":"P Spee","year":"1997","unstructured":"Spee P, Neefjes J (1997) TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin. Eur J Immunol 27:2441\u20132449","journal-title":"Eur J Immunol"},{"key":"247_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S1074-7613(00)80487-2","volume":"5","author":"B Sadasivan","year":"1996","unstructured":"Sadasivan B, Lehner PJ, Ortmann B, Spies T, Cresswell P (1996) Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity 5:103\u2013114","journal-title":"Immunity"},{"key":"247_CR25","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1182\/blood.V94.7.2461.419a26_2461_2468","volume":"94","author":"SE Pike","year":"1999","unstructured":"Pike SE, Yao L, Setsuda J, Jones KD, Cherney B, Appella E, Sakaguchi K, Nakhasi H, Atreya CD, Teruya-Feldstein J, Wirth P, Gupta G, Tosato G (1999) Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood 94:2461\u20132468","journal-title":"Blood"},{"key":"247_CR26","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/sj.gt.3302252","volume":"11","author":"JW Kim","year":"2004","unstructured":"Kim JW, Hung CF, Juang J, He L, Kim TW, Armstrong DK, Pai SI, Chen PG, Lin CT, Boyd DA, Wu TC (2004) Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther 11:1011\u20131018","journal-title":"Gene Ther"},{"key":"247_CR27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/sj.gt.3302646","volume":"13","author":"S Peng","year":"2006","unstructured":"Peng S, Tomson TT, Trimble C, He L, Hung CF, Wu TC (2006). A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Ther 13:257\u2013265","journal-title":"Gene Ther"},{"key":"247_CR28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1006\/viro.2000.0271","volume":"270","author":"Z He","year":"2000","unstructured":"He Z, Wlazlo AP, Kowalczyk DW, Cheng J, Xiang ZQ, Giles-Davis W, Ertl HC (2000) Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology 270:146\u2013161","journal-title":"Virology"},{"key":"247_CR29","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1073\/pnas.95.5.2509","volume":"95","author":"TC He","year":"1998","unstructured":"He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95:2509\u20132514","journal-title":"Proc Natl Acad Sci USA"},{"key":"247_CR30","first-page":"7234","volume":"62","author":"TY Kim","year":"2002","unstructured":"Kim TY, Myoung HJ, Kim JH, Moon IS, Kim TG, Ahn WS, Sin JI (2002) Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6\/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection. Cancer Res 62:7234\u20137240","journal-title":"Cancer Res"},{"key":"247_CR31","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1016\/j.vaccine.2004.03.057","volume":"22","author":"CJ Hsieh","year":"2004","unstructured":"Hsieh CJ, Kim TW, Hung CF, Juang J, Moniz M, Boyd DA, He L, Chen PJ, Chen CH, Wu TC (2004) Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine 22:3993\u20134001","journal-title":"Vaccine"},{"key":"247_CR32","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.4049\/jimmunol.158.7.3270","volume":"158","author":"P Brossart","year":"1997","unstructured":"Brossart P, Goldrath AW, Butz EA, Martin S, Bevan MJ (1997) Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 158:3270\u20133276","journal-title":"J Immunol"},{"key":"247_CR33","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ygyno.2005.01.046","volume":"97","author":"HS Jin","year":"2005","unstructured":"Jin HS, Park EK, Lee JM, NamKoong SI, Kim DG, Lee YJ, Jun HJ, Han BD, Bae SM, Ahn WS (2005) Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor. Gynecol Oncol 97:559\u2013567","journal-title":"Gynecol Oncol"},{"key":"247_CR34","doi-asserted-by":"publisher","first-page":"9083","DOI":"10.1128\/JVI.74.19.9083-9089.2000","volume":"74","author":"DW Liu","year":"2000a","unstructured":"Liu DW, Tsao YP, Hsieh CH, Hsieh JT, Kung JT, Chiang CL, Huang SJ, Chen SL (2000a) Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth. J Virol 74:9083\u20139089","journal-title":"J Virol"},{"key":"247_CR35","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/ijc.11726","volume":"109","author":"R Sankaranarayanan","year":"2004","unstructured":"Sankaranarayanan R, Rajkumar R, Theresa R, Esmy PO, Mahe C, Bagyalakshmi KR, Thara S, Frappart L, Lucas E, Muwonge R, Shanthakumari S, Jeevan D, Subbarao TM, Parkin DM, Cherian J (2004) Initial results from a randomized trial of cervical visual screening in rural south India. Int J Cancer 109:461\u2013467","journal-title":"Int J Cancer"},{"key":"247_CR36","doi-asserted-by":"publisher","first-page":"12180","DOI":"10.1073\/pnas.89.24.12180","volume":"89","author":"R Kirnbauer","year":"1992","unstructured":"Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89:12180\u201312184","journal-title":"Proc Natl Acad Sci USA"},{"key":"247_CR37","doi-asserted-by":"crossref","first-page":"6929","DOI":"10.1128\/JVI.67.12.6929-6936.1993","volume":"67","author":"R Kirnbauer","year":"1993","unstructured":"Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L, Lowy DR, Schiller JT (1993) Efficient self-assembly of human papillomavirus type 16 L1 and L1\u2013L2 into virus-like particles. J Virol 67:6929\u20136936","journal-title":"J Virol"},{"key":"247_CR38","doi-asserted-by":"publisher","first-page":"11553","DOI":"10.1073\/pnas.92.25.11553","volume":"92","author":"JA Suzich","year":"1995","unstructured":"Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB, Schlegel R (1995) Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92:11553\u201311557","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"247_CR39","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.AOG.0000192397.41191.fb","volume":"107","author":"C Mao","year":"2006","unstructured":"Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU, Barr E (2006) Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107(1):18\u201327","journal-title":"Obstet Gynecol"},{"key":"247_CR40","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1046\/j.1365-2249.1999.00813.x","volume":"115","author":"GJ Fernando","year":"1999","unstructured":"Fernando GJ, Murray B, Zhou J, Frazer IH (1999) Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16. Clin Exp Immunol 115:397\u2013403","journal-title":"Clin Exp Immunol"},{"key":"247_CR41","first-page":"3698","volume":"61","author":"CF Hung","year":"2001","unstructured":"Hung CF, Cheng WF, Hsu KF, Chai CY, He L, Ling M, Wu TC (2001) Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 61:3698\u20133703","journal-title":"Cancer Res"},{"key":"247_CR42","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1128\/JVI.74.6.2888-2894.2000","volume":"74","author":"DW Liu","year":"2000b","unstructured":"Liu DW, Tsao YP, Kung JT, Ding YA, Sytwu HK, Xiao X, Chen SL (2000b) Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol 74:2888\u20132894","journal-title":"J Virol"},{"key":"247_CR43","first-page":"5456","volume":"60","author":"BW Tillman","year":"2000","unstructured":"Tillman BW, Hayes TL, DeGruijl TD, Douglas JT, Curiel DT (2000) Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res 60:5456\u20135463","journal-title":"Cancer Res"},{"key":"247_CR44","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1749-6632.2000.tb06712.x","volume":"910","author":"S Basak","year":"2000","unstructured":"Basak S, Eck S, Gutzmer R, Smith AJ, Birebent B, Purev E, Staib L, Somasundaram R, Zaloudik J, Li W, Jacob L, Mitchell E, Speicher D, Herlyn D (2000) Colorectal cancer vaccines: antiidiotypic antibody, recombinant protein, and viral vector. Ann NY Acad Sci 910:237\u2013253","journal-title":"Ann NY Acad Sci"},{"issue":"Suppl 1","key":"247_CR45","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1038\/sj.gt.3302364","volume":"11","author":"N Bessis","year":"2004","unstructured":"Bessis N, Garcia-Cozar FJ, Boissier MC (2004) Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther 11(Suppl 1):S10\u201317","journal-title":"Gene Ther"},{"key":"247_CR46","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S0165-5728(99)00220-9","volume":"103","author":"K Kajiwara","year":"2000","unstructured":"Kajiwara K, Byrnes AP, Ohmoto Y, Charlton HM, Wood MJ, Wood KJ (2000) Humoral immune responses to adenovirus vectors in the brain. J Neuroimmunol 103:8\u201315","journal-title":"J Neuroimmunol"},{"key":"247_CR47","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1006\/mthe.2000.0258","volume":"3","author":"AI Kuzmin","year":"2001","unstructured":"Kuzmin AI, Galenko O, Eisensmith RC (2001) An immunomodulatory procedure that stabilizes transgene expression and permits readministration of E1-deleted adenovirus vectors. Mol Ther 3:293\u2013301","journal-title":"Mol Ther"},{"key":"247_CR48","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/eji.1830270312","volume":"27","author":"H Gahery-Segard","year":"1997","unstructured":"Gahery-Segard H, Juillard V, Gaston J, Lengagne R, Pavirani A, Boulanger P, Guillet JG (1997) Humoral immune response to the capsid components of recombinant adenoviruses: routes of immunization modulate virus-induced Ig subclass shifts. Eur J Immunol 27:653\u2013659","journal-title":"Eur J Immunol"},{"key":"247_CR49","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.4049\/jimmunol.162.9.5270","volume":"162","author":"JJ Lasarte","year":"1999","unstructured":"Lasarte JJ, Corrales FJ, Casares N, Lopez-Diaz de Cerio A, Qian C, Xie X, Borras-Cuesta F, Prieto J (1999) Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministered antigen: the role of nitric oxide. J Immunol 162:5270\u20135277","journal-title":"J Immunol"},{"key":"247_CR50","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1200\/JCO.2004.04.059","volume":"22","author":"B Sangro","year":"2004","unstructured":"Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, Benito A, Larrache J, Pueyo J, Subtil JC, Olague C, Sola J, Sadaba B, Lacasa C, Melero I, Qian C, Prieto J (2004) Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 22:1389\u20131397","journal-title":"J Clin Oncol"},{"key":"247_CR51","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/sj.cgt.7700594","volume":"10","author":"L Cordier Kellerman","year":"2003","unstructured":"Cordier Kellerman L, Valeyrie L, Fernandez N, Opolon P, Sabourin JC, Maubec E, LeRoy P, Kane A, Legrand A, Abina MA, Descamps V, Haddada H (2003) Regression of AK7 malignant mesothelioma established in immunocompetent mice following intratumoral gene transfer of interferon gamma. Cancer Gene Ther 10:481\u2013490","journal-title":"Cancer Gene Ther"},{"key":"247_CR52","doi-asserted-by":"publisher","first-page":"9221","DOI":"10.1073\/pnas.97.16.9221","volume":"97","author":"Z Hu","year":"2000","unstructured":"Hu Z, Garen A (2000) Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy. Proc Natl Acad Sci USA 97:9221\u20139225","journal-title":"Proc Natl Acad Sci USA"},{"key":"247_CR53","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/sj.gt.3300508","volume":"4","author":"JL Bramson","year":"1997","unstructured":"Bramson JL, Hitt M, Gauldie J, Graham FL (1997) Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther 4:1069\u20131076","journal-title":"Gene Ther"},{"key":"247_CR54","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/jnci\/90.24.1894","volume":"90","author":"SA Rosenberg","year":"1998","unstructured":"Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Seipp CA, Einhorn JH, Roberts B, White DE (1998) Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 90:1894\u20131900","journal-title":"J Natl Cancer Inst"},{"key":"247_CR55","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1089\/hum.2006.17.500","volume":"17","author":"Y Zhi","year":"2006","unstructured":"Zhi Y, Figueredo J, Kobinger GP, Hagan H, Calcedo R, Miller JR, Gao G, Wilson JM (2006) Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus. Hum Gene Ther 17:500\u2013506","journal-title":"Hum Gene Ther"},{"key":"247_CR56","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/hum.1997.8.1-99","volume":"8","author":"CA Mack","year":"1997","unstructured":"Mack CA, Song WR, Carpenter H, Wickham TJ, Kovesdi I, Harvey BG, Magovern CJ, Isom OW, Rosengart T, Falck-Pedersen E, Hackett NR, Crystal RG, Mastrangeli A (1997) Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 8:99\u2013109","journal-title":"Hum Gene Ther"},{"key":"247_CR57","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1161\/01.ATV.15.12.2246","volume":"15","author":"H Ueno","year":"1995","unstructured":"Ueno H, Li JJ, Tomita H, Yamamoto H, Pan Y, Kanegae Y, Saito I, Takeshita A (1995) Quantitative analysis of repeat adenovirus-mediated gene transfer into injured canine femoral arteries. Arterioscler Thromb Vasc Biol 15:2246\u20132253","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"247_CR58","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/sj.gt.3300431","volume":"4","author":"A Scaria","year":"1997","unstructured":"Scaria A, St George JA, Gregory RJ, Noelle RJ, Wadsworth SC, Smith AE, Kaplan JM (1997) Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway. Gene Ther 4:611\u2013617","journal-title":"Gene Ther"},{"key":"247_CR59","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1084\/jem.187.4.649","volume":"187","author":"P Seiler","year":"1998","unstructured":"Seiler P, Brundler MA, Zimmermann C, Weibel D, Bruns M, Hengartner H, Zinkernagel RM (1998) Induction of protective cytotoxic T cell responses in the presence of high titers of virus-neutralizing antibodies: implications for passive and active immunization. J Exp Med 187:649\u2013654","journal-title":"J Exp Med"},{"key":"247_CR60","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.4049\/jimmunol.161.10.5607","volume":"161","author":"LH Butterfield","year":"1998","unstructured":"Butterfield LH, Jilani SM, Chakraborty NG, Bui LA, Ribas A, Dissette VB, Lau R, Gamradt SC, Glaspy JA, McBride WH, Mukherji B, Economou JS (1998) Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol 161:5607\u20135613","journal-title":"J Immunol"},{"key":"247_CR61","doi-asserted-by":"crossref","first-page":"699","DOI":"10.4049\/jimmunol.163.2.699","volume":"163","author":"JM Kaplan","year":"1999","unstructured":"Kaplan JM, Yu Q, Piraino ST, Pennington SE, Shankara S, Woodworth LA, Roberts BL (1999) Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol 163:699\u2013707","journal-title":"J Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-006-0247-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-006-0247-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-006-0247-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-006-0247-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T21:49:08Z","timestamp":1683668948000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-006-0247-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12,5]]},"references-count":61,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["247"],"URL":"https:\/\/doi.org\/10.1007\/s00262-006-0247-2","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12,5]]},"assertion":[{"value":"30 June 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2006","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}